Ultragenyx Pharmaceutical (RARE) Asset Utilization Ratio (2017 - 2026)
Ultragenyx Pharmaceutical (RARE) reported Asset Utilization Ratio of 0.47 for Q1 2026, up 12.95% year-over-year from 0.42 in Q1 2025, and down 4.16% on a QoQ basis from 0.49 in Q4 2025.
Ultragenyx Pharmaceutical (RARE) has 10 years of Asset Utilization Ratio data on file, last reported at 0.47 in Q1 2026.
- Quarterly Asset Utilization Ratio rose 12.95% year-over-year to 0.47 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.47 (up 12.95% YoY) and the FY2025 annual result came in at 0.44, up 18.56% from the prior year.
- Asset Utilization Ratio slipped to 0.47 in Q1 2026 per RARE's latest filing, from 0.49 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 0.5 in Q3 2025 and bottomed at 0.23 in Q1 2022.
- The 5-year median for Asset Utilization Ratio is 0.32 (2023), against an average of 0.34.
- The widest annual swing landed in 2022, when Asset Utilization Ratio decreased 2.61%; it then jumped 52.47% in 2025.
- Tracing RARE's Asset Utilization Ratio over 5 years: stood at 0.23 in 2022, then surged by 38.48% to 0.32 in 2023, then climbed by 15.79% to 0.37 in 2024, then jumped by 34.2% to 0.49 in 2025, then fell by 4.16% to 0.47 in 2026.
- Per Business Quant, the three latest RARE Asset Utilization Ratio figures stand at 0.47 (Q1 2026), 0.49 (Q4 2025), and 0.5 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 0.60 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 0.47 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 0.29 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.37 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 0.85 |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | 0.47 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.47 |
| Dec 31, 2025 | 0.49 |
| Sep 30, 2025 | 0.50 |
| Jun 30, 2025 | 0.47 |
| Mar 31, 2025 | 0.42 |
| Dec 31, 2024 | 0.37 |
| Sep 30, 2024 | 0.33 |
| Jun 30, 2024 | 0.33 |
| Mar 31, 2024 | 0.32 |
| Dec 31, 2023 | 0.32 |
| Sep 30, 2023 | 0.32 |
| Jun 30, 2023 | 0.30 |
| Mar 31, 2023 | 0.26 |
| Dec 31, 2022 | 0.23 |
| Sep 30, 2022 | 0.23 |
| Jun 30, 2022 | 0.25 |
| Mar 31, 2022 | 0.23 |
| Dec 31, 2021 | 0.23 |
| Sep 30, 2021 | 0.24 |
| Jun 30, 2021 | 0.23 |
| Mar 31, 2021 | 0.20 |
| Dec 31, 2020 | 0.18 |
| Mar 31, 2020 | 0.10 |
| Dec 31, 2019 | 0.10 |
| Sep 30, 2019 | 0.09 |
| Jun 30, 2019 | 0.07 |
| Mar 31, 2019 | 0.07 |
| Dec 31, 2018 | 0.07 |
| Sep 30, 2018 | 0.05 |
| Jun 30, 2018 | 0.03 |
| Mar 31, 2018 | 0.02 |
| Dec 31, 2017 | 0.01 |
| Sep 30, 2017 | 0.00 |